Insider buying last 90 days
No open-market insider purchases were filed for MAZE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MAZE insider filing, plotted on the chart in Gekko.Open MAZE in Gekko
NASDAQ: MAZE
Maze Therapeutics (MAZE) Stock Analysis & Forecast
Oct 12 close
$27.70+0.59 (+2.2%)
Gekko Brief
Oct 12 closeMaze Therapeutics closed at $27.70 on 12 October 2026, +2.2% on the day. The price sits between the 50-day ($26.88) and 200-day ($32.56) moving averages, inside a 52-week range of $21.95 to $53.65. The GekkoIndex reads 51.9, in the Neutral zone, down 7 points over five sessions. Gekko Fair Value is $35.93, so the price is 22.9% below it.
The next earnings report is due on 5 November 2026, 24 days away. Over the last 6 reports the company beat the earnings estimate 4 times, with an average move of 10.3% across the report.
7 firms rate the stock: 7 buy, 0 hold and 0 sell, with a consensus target of $61.50. A typical daily move is about 6%, and a typical 20-day move about 13.1%. On the swing-trade checklist, 1 item reads supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Maze Therapeutics price vs fair value
Close $27.70200-day averageGekko Fair Value $35.93
Maze Therapeutics quick facts
- Market cap
- $1.53B
- P/E ratio
- —
- Forward P/E
- 8.5
- EPS, TTM
- −$2.48
- Revenue, TTM
- $20.00M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- —
- Volume
- 1.44M avg 945,733
- 1-year return
- −3.7%
- Typical daily move
- ±6%
- Typical 20-day move
- ±13.1%
- 50-day average
- $26.88
- 200-day average
- $32.56
- Next earnings
- Nov 5
- Shares outstanding
- 55.55M
Maze Therapeutics swing-trade checklist
Maze Therapeutics scores 1 supportive, 2 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $27.70 sits between the 50-day ($26.88) and 200-day ($32.56) averages, or the averages disagree.
See the chart - GekkoIndexmixed
51.9, Neutral
Reading 51.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
22.9% below
Price is 22.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Maze Therapeutics stock chart and price history
Maze Therapeutics closed at $27.70 on Oct 12, 2026, −3.7% over the past year, inside a 52-week range of $21.95 to $53.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +12.6%
- 3 months
- −7.3%
- 6 months
- +1.0%
- 1 year
- −3.7%
The full MAZE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MAZE in Gekko
Follow Maze Therapeutics through every session
Put MAZE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MAZE in GekkoFree for 7 days. No credit card required.
About Maze Therapeutics
Maze Therapeutics is a clinical stage biopharmaceutical company focused on small molecule precision medicines for kidney and metabolic conditions in the United States. Its most advanced candidate, MZE829, targets apolipoprotein L1 and is being studied in a phase II trial for patients with APOL1 kidney disease. Another program, MZE782, is an oral inhibitor positioned to enter phase II trials for phenylketonuria and chronic kidney disease, while MZE001 is an early-stage candidate aimed at Pompe disease through inhibition of muscle-specific glycogen synthase.
Beyond its own pipeline, Maze Therapeutics has entered licensing arrangements that extend its research reach. It works with Trace Neuroscience on a discovery program targeting UNC13A, with Shionogi & Co. on the research, development, manufacturing and commercialization of MZE001, and with Neurocrine Biosciences on a discovery effort directed at ATXN2.
The company was founded in 2017 under the name Modulus Therapeutics before adopting the Maze Therapeutics name in September 2018. It is headquartered in South San Francisco, California, and its shares trade on the NASDAQ under the ticker MAZE.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- mazetx.com
Maze Therapeutics GekkoIndex: the smart money zone
Maze Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.9, in the Neutral zone, down 7 points over five sessions.
51.9Neutral
Down 7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 34 | −0.7% | −5.5% | ||
| Accumulation | 132 | +0.3% | +7.9% | ||
| Neutral (current zone) | 218 | +2.4% | +8.6% | ||
| Distribution | 35 | +1.6% | −1.5% | ||
| Selling | 1 | Too few readings yet | |||
Average MAZE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MAZE price, zone by zone.Track MAZE in Gekko
Is Maze Therapeutics stock overvalued? Gekko Fair Value
Maze Therapeutics trades 22.9% below Gekko Fair Value of $35.93, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Maze Therapeutics shares are worth, recalculated every trading day.
$35.93
Gekko Fair Value, Oct 10, 2026
22.9% Undervalued
At the end of Aug 2026 the price was 47.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MAZE in Gekko
Maze Therapeutics insider and Congress trading
No open-market insider purchases were filed for Maze Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MAZE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MAZE, plotted on the chart in Gekko.Open MAZE in Gekko
Maze Therapeutics earnings: next date and track record
Maze Therapeutics reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 4 of its last 6 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.76
- Revenue estimate
- $333K
4 of 6reports beat the EPS estimate
±10.3%average move across the report
3 of 6reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | −$0.76 est −$0.72 | — est $2.86M | +1.3% |
| May 12, 2026 | −$0.45 est −$0.62 | $20.00M est $10.63M | +5.6% |
| Mar 25, 2026 | −$0.65 est −$0.69 | $20.00M est $375K | −35.3% |
| Nov 6, 2025 | −$0.66 est −$0.74 | — | −5.5% |
| Aug 12, 2025 | −$0.77 est −$0.79 | — est $3.13M | +1.0% |
| Mar 31, 2025 | −$18.32 est $0.45 | — | −13.3% |
| Dec 6, 2024 | −$0.06 | $2.50M | — |
| Jun 30, 2024 | $3.18 | $165.0M | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Maze Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Maze Therapeutics is $61.50, +122.0% from the last close, from 7 firms rating the stock in the last 90 days.
$61.50consensus 12-month target, +122.0% from the last close
Now $27.70Avg $61.50
Low $46High $110
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | H.C. Wainwright | $110 | +297.1% |
| Sep 23 | Wedbush | $48 | +73.3% |
| Sep 23 | Citi | $50 | +80.5% |
| Sep 22 | Truist Financial | $64 | +131.0% |
| Sep 22 | H.C. Wainwright | $110 | +297.1% |
+8.6%average 20-day move after past Neutral readings
±6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Maze Therapeutics market cap and key statistics
Maze Therapeutics’s market cap is $1.53B and revenue of $20.00M over the last twelve months.
Valuation
- Market cap
- $1.53B
- Forward P/E
- 8.5
- EPS, TTM
- −$2.48
- Gekko Fair Value
- $35.93
Trading
- Volume
- 1.44M
- Avg volume, 20 days
- 945,733
- 52-week high
- $53.65
- 52-week low
- $21.95
- Shares outstanding
- 55.55M
Financials
- Revenue, TTM
- $20.00M
- Profit margin
- 0%
- Return on equity
- -37.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±6%
- Typical 20-day move
- ±13.1%
Maze Therapeutics stock news this week
2 headlines about Maze Therapeutics from the past week, newest first, each linking to the publisher.
Maze Therapeutics peers
Maze Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Maze Therapeutics stock FAQ
What is Maze Therapeutics’s market cap?
Maze Therapeutics’s market cap is $1.53B at the Oct 12, 2026 close of $27.70, with 55.55M shares outstanding.
What is the Maze Therapeutics stock forecast?
The consensus analyst 12-month price target for Maze Therapeutics is $61.50, +122.0% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Maze Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Maze Therapeutics is undervalued: the Oct 12, 2026 close of $27.70 is 22.9% below Gekko Fair Value of $35.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Maze Therapeutics report earnings next?
Maze Therapeutics is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.76 per share on revenue of $333K. Maze Therapeutics beat the earnings estimate in 4 of its last 6 reports, moving 10.3% on average across the report.
What is Maze Therapeutics’s 52-week high and low?
Maze Therapeutics’s 52-week high is $53.65 and its 52-week low is $21.95; it closed at $27.70 on Oct 12, 2026, −3.7% over the past year.
Is Maze Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 4 items with data read as supportive (fair value), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Maze Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.